Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROKIDNEY CORP.PROK · Entity 5181 | Chief Financial Officer | March 01, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROKIDNEY CORP.
Report date March 01, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.24 · Expires 2036-03-01 | Direct | 600,000 |
Reported balance
After 2026-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-01 · Grant · Acquired 600,000 · Balance 600,000 F1: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2026 Filed Mar 3, 2026 12:59 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 600,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001193125-26-086730 · ownership.xml · derivative · entry 1 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires 2036-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:41 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 650,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0000950170-25-032247 · ownership.xml · derivative · entry 1 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Class A Ordinary Shares · 650,000 shares Expires 2035-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2025. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:13 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 275,000 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0000950170-24-025919 · ownership.xml · derivative · entry 1 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Class A Ordinary Shares · 275,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2024. Read SEC document |
| January 16, 2023 Filed Jan 18, 2023 21:10 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option, right to buy · Derivative | 290,000 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001209191-23-003711 · doc4.xml · derivative · entry 1 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Class A Ordinary Shares · 290,000 shares Expires 2033-01-16 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on January 16, 2023. Read SEC document |
| October 20, 2022 Filed Oct 24, 2022 21:49 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantEmployee stock option (right to buy) · Derivative | 325,170 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-054427 · doc4.xml · derivative · entry 1 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,170 Underlying: Class A Ordinary Shares · 325,170 shares Expires 2032-10-20 F1 · derivative.exercise_date: The option vests in substantially equal monthly installments over the four year period beginning on October 19, 2022. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:30 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantCommon Units in ProKidney LP · Derivative | 716,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012373 · dp177036_4-coulston.xml · derivative · entry 2 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,850 Underlying: Class A Ordinary Shares · 716,850 shares Expires not disclosed F3 · security: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F3 · derivative.exercise_price: Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis. F4 · derivative.exercise_price: These 321,615 Common Units and 395,235 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. F4 · derivative.exercise_date: These 321,615 Common Units and 395,235 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. F4 · derivative.expiration_date: These 321,615 Common Units and 395,235 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire. Read SEC document |
| July 11, 2022 Filed Jul 14, 2022 01:30 UTC | PROKIDNEY CORP. PROK · Entity 5181 | GrantClass B Ordinary Shares · Derivative | 716,850 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-22-012373 · dp177036_4-coulston.xml · derivative · entry 1 Coulston James · CIK 0001936203 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 716,850 Underlying: Class A Ordinary Shares · 716,850 shares Expires not disclosed F1 · derivative.exercise_price: Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis. F2 · derivative.exercise_price: These 321,615 Class B Ordinary Shares and 395,235 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.exercise_date: These 321,615 Class B Ordinary Shares and 395,235 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. F2 · derivative.expiration_date: These 321,615 Class B Ordinary Shares and 395,235 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.